Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We have read your past posts.
Not sure how you can call a company in Phase 3 clinical trials, with a promising new drug therapy, a scam.
We love scooping up the shares of those who are disheartened and have exhausted their patience.
Micro-cap investing is not for everyone.
https://altitradepartners.blogspot.com/2021/04/these-are-times-that-test-micro-cap.html
Would you please refrain from disparaging our CEO and the BIOF Board of Directors?
Take time to perform some research on Ben's background regarding other technologies that he has developed and successfully commercialized over the years.
Specifically, Solar Excel BV and Novameer BV.
Also, remember that both Ben and Anthony saved this company from going under. Without them you would have no investment in BIOF, just a tax write-off for ALLM.
It's easy to be an armchair quarterback.
Our position is, and always has been, that we view our investment stake in CRXM as a LEAP option (Long-Term Equity AnticiPation Securities) on the FDA approval of Generx.
We believe that ultimately, this investment will have a binary outcome; either the company with hit a grand slam or they will strike out.
We are prepared for another CELH or GLUC, and we are prepared to lose 100% of our investment.
We really could care less about the fact that the shares do not trade, since we are not interested in trading them.
We followed this stock for over 20 years, and never once took a position in the shares until March of this year, when we felt that the timing was right, given a number of various factors.
We are in CRXM now, and we are in it for the long haul.
We will let others play the typical game of trading in-and-out, and trying to time the short-term price swings.
We can't be bothered with such nonsense.
We like to say that traders will step over dollars to pick up pennies.
If you don't believe in CRXM management, we would suggest that you sell your shares and move on to another investment.
We have staked our claim, and will wait patiently for the final outcome.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166007176
Things are what they are, and will follow their natural course in due time.
There are too many nervous nellies, and Monday morning QB's on this board.
Everyone just needs to take a chill pill and relax.
That is incorrect.
All shareholders, whether public or private, that own greater than 10% of the outstanding shares of a publicly-traded company are required to file any changes in their ownership with the SEC, under The Exchange Act.
If greater than a 10% ownership stake, they must file within 2 business days after any change in their status.
https://www.sec.gov/smallbusiness/goingpublic/officersanddirectors
While Nostrum is, in fact, a private company, and falls outside of the SEC filing requirements for their own capital structure (they have no public shareholders), the fact that they own an equity stake in a publicly-traded company requires them to file all necessary SEC forms pertaining to changes in their ownership position.
Saber-rattling aside, taking such an aggressive posture will accomplish very little, given the current capital structure and Nostrum's ownership stake in CRXM.
We believe in CRXM management and what CEO Chris Reinhard is doing. Our impression is that he has a very good working relationship with the folks at Nostrum.
It would make no sense to upset the apple cart, at this point.
Quite frankly, what happens in the short run is of no consequence to us. If the company does not complete their filings on time, it's not the end of the world.
We will still own shares of a company with a potential blockbuster drug that could send the valuation of CRXM soaring with an FDA approval of Generx.
Since we are not interested in flipping our shares for small profits, or trying to time the ebbs and flows of the market price as a trader, we would be just fine if the shares didn't trade for awhile (or at all for that matter).
We simply view the situation much the way we would if we owned CRXM as a private company, with no public market for our shares.
If you are looking to trade CRXM shares, we understand your concern. If you are planning on holding CRXM shares for the next 3-5 years, as we are, none of this should really matter.
Why on earth would Nostrum choose to become a public company, when they currently have the best of both worlds?
As a private company they don't have the costs and burden of regulatory requirements, while at the same time they have a huge controlling interest in publicly-traded CRXM.
I just confirmed with Interactive Brokers that they are no longer allowing investors to purchase shares of CRXM.
Ally will not allow investors to purchase any stock that falls below a penny. In other words, no sub-penny trades.
That should say HAVE NOT.
As a result of Covid-19, we have traveled to the company's offices recently.
What is interesting about this press release is that it uses the word "believes" and does not mention GEVO actually getting into the production of cellulosic SAF.
It might be time to talk with the folks at GEVO.
We have been focused on investing in Micro-caps for over 40 years.
When we hear investors grousing constantly, and losing patience, we know that its time to get our catcher's mitt out of the closet.
https://altitradepartners.blogspot.com/2021/04/these-are-times-that-test-micro-cap.html
In doing a bit more research regarding yesterday's press release, we believe that the importance of the news failed to be understood by many investors.
https://finance.yahoo.com/news/blue-biofuels-files-two-patents-160600789.html
Here are two articles, which we highly encourage investors to read.
https://www.azonano.com/article.aspx?ArticleID=3139
https://norwegianscitechnews.com/2017/11/super-material-can-replace-plastic/
Go back and look at a two year chart of GEVO.
https://www.stockscores.com/charts/charts/?ticker=gevo
When would you have wanted to own it?
If you look at their history, they had a string of failures before they found the right niche.
BIOF may be a few years behind GEVO, but we are willing to buy at these extremely attractive levels and wait.
If they are successful, the payoff could be enormous.
It's a lottery ticket in the eyes of some investors, but, remember, "you have to be in it to win it".
What the GEVO news does, however, is validate the importance of SAF, and also shows that there is a huge market for companies supplying the airlines with it.
So, in that regard, it is relevant.
https://altitradepartners.blogspot.com/2021/07/gevo-allm-why-saf-jet-fuel-technology_88.html
Over 40 years of experience trading and investing in the stock market.
We expect the price to get whipped around for at least a few more days.
That, along with heavy volume, will likely garner the attention of BIOF management.
A 48% decline in price over a period of only 8 trading days will often do that.
Here is the link to the presentation that you are referring to:
https://genebiotherapeutics.com/wp-content/uploads/2021/07/Gene-Biotherapeutics-Presentation-Final-.pdf
There is some great information to be found here, for sure.
In account #1, CRXM was 100% of your investable assets.
In account #2 it was 88%, and in account #3, it was 87%.
It's no wonder why you suddenly became nervous and fearful, and decided to sell.
There was just too much at risk holding such concentrated positions.
We also hold a number of concentrated positions in multiple accounts, and we understand that it can be very nerve-racking.
We can certainly empathize with how you felt, along with your motive for selling to protect your capital.
Judge each investment on its own, unique, individual merits.
Don't make the mistake of projecting one situation on to another one.
Remember, no two investment opportunities are the same.
They may have similarities, but they are never identical, and the final results shouldn't be either.
It’s the difference between a fear-based and a faith-based mentality.
"I'm afraid that they won't get this done and I will lose all of the money that I have invested, vs. I am confident that they will get this done and I am going to make money in the long run."
You have offered convincing proof by sharing screenshots of your Schwab statements. The only thing we have a hard time understanding in why you bailed on something you obviously had a great deal of conviction in at one time?
https://altitradepartners.blogspot.com/2021/09/blue-biofuels-base-remains-in-place.html
We are still up over 100% in value from where we were a year ago.
Covid-19 has caused many companies to push back projected timelines that, otherwise, would have easily been met.
The supply chain disruption has taken a toll on part suppliers, which in turn has affected the timeline for many corporate plans and initiatives.
Just look at what's happening in the automobile industry, as an example.
It's frustrating, for sure, but we remain confident.
It wouldn't surprise us to see lawsuits filed against certain broker-dealers who have taken these restrictive measures ahead of the September 28th deadline.
There are quite a few OTC pink sheet companies that will become current in the next few weeks. If restrictions still remain in place, and are not lifted in a timely manner, it could create a litigious environment.